<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105985">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02032862</url>
  </required_header>
  <id_info>
    <org_study_id>920157</org_study_id>
    <nct_id>NCT02032862</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Sage Tablets Compared to Placebo in Menopausal Patients With Hot Flushes and Sweating</brief_title>
  <official_title>Multicentric, Randomized, Double Blind Study for Assessment of Efficacy and Tolerability of Sage Tablets Compared to Placebo in Menopausal Patients With Hot Flushes and Sweating</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioforce AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioforce AG</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sage tablets ( 3400 mg extract from fresh sage leaves, DER 1:17)  in a once daily
      application over 12 treatment weeks are compared against placebo in 200 menopausal patients
      with ≥ 5 hot flushes daily and a Hyperhidrosis Scale score ≥ 2
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from Baseline Hyperhidrosis Disease Severity Scale</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Menopause Rating Scale / MRS</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Modified Dem Tect</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Menopausal Hot Flushes</condition>
  <arm_group>
    <arm_group_label>Sage tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sage extract, 3400 mg , DER 1:17, in once daily application over 12 weeks treatment phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo,  matching  the verum in size and appearance, in once daily application over   12 weeks  treatment phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sage extract, 3400 mg , DER 1:17</intervention_name>
    <arm_group_label>Sage tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Menopausal since ≥ 1 year

          -  ≥ 5 hot flushes /24 hours

          -  Hyperhidrosis Scale score ≥ 2

        Exclusion Criteria:

          -  Affections like asthma, COPD, depression, diabetes, epilepsy, hyper- and
             hypothyreosis, malign tumours
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Silvia Bommer, Dr. med.</last_name>
    <phone>0041 7145</phone>
    <phone_ext>46204</phone_ext>
    <email>s.bommer@bioforce.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dr. M. Morger</name>
      <address>
        <city>Saint Gallen</city>
        <state>St. Gall</state>
        <zip>9000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Morger, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 9, 2014</lastchanged_date>
  <firstreceived_date>January 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>menopause, hot flushes, hot flashes, salvia, sage, sweating</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Flushing</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
